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Summary
Setting: Tuberculosis Research Centre, Chennai and Madurai, South India.
Objective:  To assess response to treatment, relapse and emergence of MDR TB in newly diagnosed patients with sputum-
positive tuberculosis using an intermittent intensive phase followed by a non-rifampicin continuation phase.
Design: Patients were treated in a controlled clinical trial with 2HRZE
3
/6HE with thrice-weekly direct dosing in the
intensive phase and once-weekly with six doses self-administered in the continuation phase. Clinical and bacteriologic
evaluation was done every month for 24 months.
Results: The overall outcome was good, with 92% favourable response (cure) and 4.8% relapse in 450 patients including 103
who did not receive extension of intensive phase for positive smear, 38 with initial H-resistant cultures, 4 with MDR TB and
15 who received less than 75% of chemotherapy. In 392 patients with drug-susceptible cultures, 96%were cured and only 4%
relapsed.  There was no emergence of MDR TB among failures and relapses; toxicity was low.
Conclusion:  Newly-diagnosed Category I patients can be effectively treated with this regimen without emergence
of MDR TB. It has immense potential in programmes where directly observed therapy cannot be ensured throughout,
and when rifampicin is contraindicated in HIV-TB patients who require concomitant therapy with anti-retroviral
drugs.
Key Words: New sputum positive tuberculosis, intermittent intensive phase, non-rifampicin continuation phase,
emergence of multi-drug resistant TB, HIV-TB.
EVALUATION OF A NON-RIFAMPICIN CONTINUATION PHASE (6HE)
FOLLOWING THRICE-WEEKLY INTENSIVE PHASE FOR THE TREATMENT OF
NEW SPUTUM POSITIVE PULMONARY TUBERCULOSIS
INTRODUCTION
The control of tuberculosis assumes
importance and urgency particularly in disease
endemic countries which bears most of the burden
of the disease.  In several African nations, the co-
existing pandemic of HIV/AIDS has multiplied the
problem of treating TB in patients with HIV. In
addition, increasing number of patients with multi-
drug resistant tuberculosis (MDR TB) poses further
challenges to control programmes.
The globally recommended DOTS strategy
of the World Health Organization (WHO) for newly-
diagnosed sputum positive patients (Category I),
gives an option to use a daily or thrice-weekly initial
intensive phase of HRZE/S* for two months followed
by four months of RH either daily or thrice-weekly,
or HE daily for six months in the continuation phase1.
Daily regimens with 2SHRZ in the intensive phase
followed by HT* for six months2 and 2HRZE
followed by HE for six months3 have been studied
and found to be effective in controlled clinical trials.
However, the efficacy of thrice-weekly intensive
phase followed by HE in the continuation phase has
not been evaluated in controlled trials. A thrice-weekly
rhythm has the advantage of easy implementation as
directly observed therapy (DOT), especially during
the critical initial intensive period of treatment. A daily
rhythm using HE in the continuation phase has the
advantage that, even if given once-weekly, patients
are more likely to remember to take the drugs daily.
Since rifampicin is not administered in this phase,
the possibility of emergence of multi-drug resistance
(MDR), among patients already harbouring H-
resistant bacilli, is minimized. This regimen, if
effective, will be of use in areas where directly
observed treatment is difficult throughout the
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treatment phase or when rifampicin cannot be used,
as in patients with HIV-TB who require concurrent
anti-retroviral and anti-tuberculosis treatment.
The primary objectives of this study were
to a) evaluate outcome of 2HRZE
3
/6HE by
quantifying treatment failures and relapses, and b)
assess the emergence of MDR TB.
In addition, we examined the impact of
extension of the intensive phase by 12 doses in
patients who had a positive smear at 2 months by
comparing outcome with a group of patients who
did not receive extension. The results of this part of
the study will be published separately.
PATIENTS AND METHODS
Patients aged 12 years or more, who
attended chest clinics of the Tuberculosis
Research Centre (TRC) were assessed for
inclusion to this study.  Those who had at least
two sputum smears positive for acid–fast bacilli
(AFB)* and who had not received prior chemo-
therapy for tuberculosis for one month or more
were recruited.  Criteria for admission were as in
previous studies by the TRC4. In addition, patients
with severe visual defects other than refractory
error were excluded.
The study was approved by the Scientific
Advisory Committee of the TRC and by the
Institutional Ethics Committee. All participants gave
informed consent, after information regarding the
study regimen and procedures was given to them in
their own language.
Intervention
Patients received an initial intensive phase
of the four-drug combination consisting of H
(600mg), R (450mg), Z (1500mg) and E (1200mg)
three times a week for 24 doses. Patients weighing
60 kilogram or more at intake, received 600mg of
R. A maximum period of one month was allowed
for compensation of any doses missed during this
phase.  Each dose was given under the direct
observation of a clinical nurse.
All patients received 6HE daily in the
continuation phase: H (300mg) and E (800mg)
supplied to the patient on a once weekly basis. The
first dose was administered under direct observation
and the remaining six doses for the week supplied
for self-administration.  Missed doses were not
compensated during this phase.
For the first 226 patients the continuation
phase was started irrespective of the smear results
at the end of intensive phase. As a result 103 patients
did not receive additional 12 doses despite having a
positive smear. For the next 241 patients, the initial
phase was extended by 12 doses for 112 patients
with positive smear at two months as recommended
in the WHO guidelines1. The two groups have been
analyzed together as well as separately. Since there
was no statistically significant difference between
the groups the overall results are presented in this
paper.
Pre-treatment investigations
A chest radiograph PA view, examination by
smear and culture for Mycobacterium tuberculosis
of four sputum samples (2 overnight;2 spot
collections) and drug-susceptibility testing for H, R,
E and S on two pre-treatment cultures were
undertaken.  Identification tests were carried out on
all positive cultures. Hepatic and renal functions and
haematological parameters were assessed. A detailed
clinical examination, including tests for visual acuity
and colour differentiation using the Ishihara chart
were carried out.
Investigations during treatment and follow-up
Patients were reviewed every month by a
physician. Three sputum specimens (two overnight,
one spot) were examined by smear and culture for
M. tuberculosis every month until the end of the
treatment phase.  One positive culture at each month
was tested for drug susceptibility to H, R and E.
A chest radiograph was taken at end of 1st
month and end of treatment phase for all patients.
An additional radiograph was taken if the sputum
TUBERCULOSIS  RESEARCH  CENTRE
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was reported as positive by smear at four months or
later, or if clinical symptoms warranted one, as judged
by the physician.
All patients were closely monitored for
adverse drug reactions (ADRs), and any modification
of the study regimen was recorded.  Whenever a
complaint suggestive of ADR was made, a team of
physicians assessed the patient and detailed
examination was carried out and all findings
documented.
From the end of treatment until the 24th
month, two sputum samples (one overnight, one
spot) were collected each month and subjected to
smear and culture for M. tuberculosis.  A chest
radiograph was taken at 12 and 24 months and
reviewed by a physician.
General Management
Patients were treated on a domiciliary basis.
During the initial intensive phase, they attended three
times a week to have their treatment under direct
observation in the clinic. During the continuation
phase they attended once-weekly. A health care
worker carried out surprise home visits and pill-
counts.  If any excess packets of HE were found,
they were retrieved and these doses were
documented as “missed” on the treatment card
maintained at the clinic.   If patients failed to attend
on the allotted day in either phase of treatment, their
homes were visited and all attempts made to retrieve
them.
Patients were re-questioned for additional
information about prior chemotherapy at the first
monthly examination, and when any drug resistance
was reported.
Bacteriological procedures
Sputum smears were examined by
fluorescence microscopy5 and specimens were
processed for culture by a modified Petroff’s method
using Lowenstein-Jensen medium.   Positive cultures
were confirmed as M. tuberculosis employing key
identification tests6, and drug susceptibility tests to
H, R and E by the minimal inhibitory concentration
method7 and S by resistance ratio method7 were
carried out.  The definitions of drug resistance were
the same as in previous studies for H8 and R8.
Definitions used
Favourable response (Cure): If all six cultures
were negative during the last two months of
chemotherapy or if a culture was positive during the
last two months but became negative subsequently
without additional chemotherapy.
Unfavourable response: When (a) two or more
cultures were positive in the last two months of
treatment, including at least one in the last month,
with at least one culture growing 20 colonies or more,
or (b) persistent bacteriological positivity or
radiographic and / or clinical deterioration warranting
change of chemotherapy, or (c) death due to
tuberculosis during the treatment phase or (d) change
of treatment due to adverse drug reactions.
Bacteriological relapse requiring treatment
Two or more cultures positive for M.
tuberculosis in a 2-month period, at least one with a
growth of 20 colonies or more and associated with
a positive smear, occurring during the follow-up
period.
RESULTS
A total of 467 patients were admitted to the
study between December 1998 and May 2001. Eight
patients did not fulfill eligibility criteria: cultures
negative for M. tuberculosis (4), prior anti-TB
treatment for more than one month (2), and identified
to have severe visual defect after recruitment (2).
Nine others were excluded due to non-availability of
smear results at the end of two months. Of the
remaining 450 patients, 70% were male, mean age
was 31.4 years (range 13 to 65) and mean weight
was 41.5 kg. (27.4 to 74.2). Smear grading was 2
plus or more in 70 % of patients and culture grade
was 3 plus in 80%. Pre-treatment cultures were
susceptible to both H and R in 408 (91 %), resistant
to H in 38 (8.4%) and HR in 4 (0.9%) patients.
CATEGORY  I  REGIMEN WITH 6HE  CONTINUATION PHASE
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Overall results
Response to treatment and relapse during
follow-up
At the end of treatment, 413 (92 %) of 450
patients had a favourable response (cure).  Thirty-
seven patients had an unfavourable response (29
bacteriological failure, 4 TB deaths, two change of
treatment due to adverse drug reactions, and two
developed extra-pulmonary TB while on treatment).
Of the 413 patients with favourable response (cure),
20 (4.8%) relapsed during the follow-up
(Figure 1).
Emergence of drug resistance
In all, 57 patients either failed or relapsed
(Figure 1). Four of them had pre-treatment MDR
TB.  None of the remaining 53 patients emerged with
R-resistance or developed MDR TB at the time of
failure or relapse. Seven had emergence of single
drug resistance to H.
Sub-group analysis
Of the 392 patients who had initially
susceptible organisms to H and R and had received
75% or more of prescribed chemotherapy, 378 (96%)
had a favourable response at the end of treatment.
Six patients were excluded from relapse analysis
(four non-TB deaths, one treated for Hansen’s
disease with a R-containing regimen and one default),
although the last available sputum specimens were
negative in all these patients. Of the remaining 372
followed upto 24 months, 15 (4%) relapsed (Table
1). Among 37 patients with cultures initially resistant
to H, 21 (57%) had a favourable response and 3 had
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Exclusions      8          
Ineligible: 
Cultures negative for M. tuberculosis  4 
Previous Rx >  1 month   2 
Severe visual defect    2             
Eligible                                         459 
Sputum not available at 2 months               9 
No. in analyses     450      
Favourable response (cure) at the end of treatment    413 (92%)   
Unfavourable response     37 (8%) 
Relapses      20 (4.8%)             
    
 
Total symptomatics 
assessed N = 2202 
Patients admitted 
N= 467 
Inclusion criteria not met 1396 
Refused to participate  339 
Admitted   467 
Figure: Schematic presentation of all eligible patients in the controlled clinical trial to evaluate the
efficacy of a non-rifampicin continuation phase following a thrice-weekly intensive phase in
the treatment of newly diagnosed smear positive pulmonary tuberculosis, South India.
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a bacteriologic relapse. Of 4 patients who had
organisms resistant to both H and R, three had an
unfavourable response and one relapsed. The
remaining 17 patients had received less than 75% of
the study regimen and, therefore, not included in the
efficacy analysis.
Adverse reactions
Symptoms suggestive of any adverse drug
reactions were reported by 87 (19%) patients: gastro-
intestinal reactions by10%, arthralgia 4.6%,
cutaneous reactions 5.2%, giddiness 1.3% and
hepatotoxicity 0.4%. Reactions were considered
severe in two: Z terminated in one patient with severe
itching and H in another for jaundice. In all other
patients, the reactions were mild.  None had ocular
toxicity.
DISCUSSION
The findings of this study indicate that the
regimen with 6HE in the continuation phase following
a thrice-weekly intensive phase can be used to treat
new sputum-positive TB patients (Category I).  The
treatment-outcome in patients with initially drug-
susceptible disease was good, with a cure rate of
96%  and  4% relapse (Table 1).  This finding
assumes importance for TB control programmes
considering that the vast majority - 80% or more -
of patients in this category harbour bacilli susceptible
to both H and R9-11.   An earlier study by TRC3, which
evaluated a similar regimen with a daily intensive
phase (2HRZE/6HE), showed 96% cure and 4%
relapse in 245 patients with drug-susceptible cultures
who received less than one month of prior
chemotherapy. These findings indicate that intensive
phase with intermittent treatment did not compromise
efficacy of the regimen in these patients. An intermittent
intensive phase has the advantage that it can be more
easily implemented as DOT under TB control
programme conditions. Although the outcome in the
presence of initial H-resistance was not as good (Table
1), none of the failures or relapses had emergence of
additional R-resistance. Recently an international multi-
centric study, comparing a daily 8-month regimen and
an intermittent intensive phase 8-month regimen, has
also reported similar results12. However, emergence
of drug resistance was not looked into in that study.
Adverse reactions such as hepatitis and
arthralgia were less with the thrice-weekly intensive
phase used in this study compared to the daily rhythm
in the earlier study3 (0.4% vs 4%; 5% vs 25%,
respectively). However, gastro-intestinal reactions were
more common (10% vs 3%).
Further, in this study, none of the 53 failures
and relapses had developed MDR TB. A programme-
based study from Malawi 13 also reports that none of
the failures to first line treatment with 6HE in the
continuation phase following either 2SHRZ or 2HRZE
3
had MDR TB. Another study from Vietnam however,
reports a higher rate of MDR TB among patients
who failed on Category I regimens under programme
conditions using the same continuation phase14.  This
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Drug susceptibility 
Profile* 
Total 
patients 
Favorable 
response at end 
of treatment 
No.               % 
Total patients Relapses 
 
 
No.             % 
Susceptible to HR 392 378               96 372 15             4.0 
Resistant to H   37   21               57   21   3           14.0 
Total 429 399               93 393 18             4.6 
 
* 4 MDR: 3 failed and one relapsed 
 
 
Table: Response at the end of treatment and relapse in patients who received more than 75% of
chemotherapy in the control clinical trial, Chennai, South India
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is at variance with the findings of our studies and the
report from Malawi. A recent report from Bangladesh11
indicates that there has been a significant decrease in
MDR TB after 1995 when 2HRZE/6HT was
introduced as the Category I regimen in the national
programme, further supporting our finding.
In a recent analysis of results of an earlier
study by TRC15, we examined the emergence of MDR
TB among patients treated with HR
2
 in the continuation
phase following the same intermittent intensive phase.
Of 1043 patients 10% had either failed or relapsed,
and of these 13 (12%) emerged with MDR TB. Higher
rates of emergence of MDR TB have been reported
from Thailand10 and Peru16 using HR in the continuation
phase under programme conditions.
It is evident, therefore, that patients who fail
on regimens with a non-rifampicin continuation phase,
even from among those with initially H-resistant bacilli,
can be successfully treated with the current re-
treatment regimen of 2SHRZE/1HRZE/5HRE
recommended by WHO, as there was no emergence
of MDR TB. This is an important finding for TB control
programmes.
A limitation of this study was that we did not
use a concurrent control. We, however, have historical
controls from recent trials done in the same setting.
The efficacy of daily HRZE followed by HE in the
continuation phase3 and HRZE
3
 followed by HR
2
 have
been demonstrated17. Our intention was to evaluate a
regimen with an intermittent intensive phase with HE
in the continuation phase.
In the current context of increasing
proportions of HIV seropositivity among patients with
tuberculosis, greater numbers of such patients may
require treatment for both diseases. Malawi has
reported 77% HIV sero-prevalence among TB
patients18. The UNAIDS is projecting a rapidly
expanding epidemic of HIV/AIDS across Asia, which
also has the highest burden of TB. There is evidence
to suggest drug interactions between rifampicin and
both protease inhibitors and nevirapine,19-22 resulting in
sub-optimal serum levels, which could increase the
chances of emergence of resistance to these drugs.
Our study regimen with 6HE in the continuation phase
can therefore be given safely with anti-retroviral therapy
after the intensive phase of treatment for tuberculosis.
However, only one patient in the current study was
HIV positive and had a favourable outcome. Clearly,
more studies are needed to establish its utility in HIV
positive patients.
This regimen with a non-rifampicin
continuation phase (2HRZE
3
/6HE), with an overall
favourable response (cure) of 92% and a relapse rate
of under 5%, has the following advantages: a) the
thrice-weekly intensive phase is eminently suited for
directly observed therapy, which is a key component
of the DOTS strategy under TB control programmes
worldwide, b) with once-weekly supply in the
continuation phase it can be used in regions where
DOT cannot be ensured throughout the treatment
phase, c) with virtually no emergence of MDR TB,
the failures and relapses of this regimen can be
successfully treated with the current re-treatment
(Category II) regimen and d) for the increasing
numbers of patients requiring concomitant
chemotherapy for HIV and TB, anti-retroviral therapy
can be started as soon as the rifampicin containing
initial intensive phase is completed.
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